It's probably enough to set a cap instead of none -- that would seem unfair to the outside world.  We could also tie removal of the cap to quarters of increasing profitability or something like that.

 

However, my beef is that the board and management are stacked with buddies from prior companies who apparently don't have much knowledge of the pharma industry.